Listed

Camp4 Therapeutics Corp

CAMPNasdaqCIK 1736730HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$1.8m, Q2 FY2026
Operating income−$13.4m, Q2 FY2026
Net income−$33.5m, Q2 FY2026
Camp4 Therapeutics Corp, income statement, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31period not labelled2024-03-31period not labelled2024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.4Revenue, period not labelled, three months to 2023-09-30$350.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure0.0Revenue, period not labelled, three months to 2023-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-27, accession 0001736730-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, period not labelled, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure0.0Revenue, period not labelled, three months to 2024-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure0.7Revenue, Q4 FY2024, three months to 2024-12-31$652.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.9Revenue, Q1 FY2025, three months to 2025-03-31$858.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure1.5Revenue, Q2 FY2025, three months to 2025-06-30$1.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure0.8Revenue, Q3 FY2025, three months to 2025-09-30$795.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure0.3Revenue, Q4 FY2025, three months to 2025-12-31$348.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure1.3Revenue, Q1 FY2026, three months to 2026-03-31$1.3m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure1.8Revenue, Q2 FY2026, three months to 2026-06-30$1.8m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Research and development$m9.8Research and development, period not labelled, three months to 2023-09-30$9.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure10.7Research and development, period not labelled, three months to 2023-12-31$10.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-27, accession 0001736730-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure9.7Research and development, period not labelled, three months to 2024-03-31$9.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure9.4Research and development, period not labelled, three months to 2024-06-30$9.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure9.7Research and development, Q3 FY2024, three months to 2024-09-30$9.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure10.0Research and development, Q4 FY2024, three months to 2024-12-31$10.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure10.1Research and development, Q1 FY2025, three months to 2025-03-31$10.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure10.3Research and development, Q2 FY2025, three months to 2025-06-30$10.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure9.4Research and development, Q3 FY2025, three months to 2025-09-30$9.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure8.4Research and development, Q4 FY2025, three months to 2025-12-31$8.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure10.2Research and development, Q1 FY2026, three months to 2026-03-31$10.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure10.8Research and development, Q2 FY2026, three months to 2026-06-30$10.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Operating income$m(12.3)Operating income, period not labelled, three months to 2023-09-30−$12.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure(13.5)Operating income, period not labelled, three months to 2023-12-31−$13.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-27, accession 0001736730-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure(12.9)Operating income, period not labelled, three months to 2024-03-31−$12.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure(12.7)Operating income, period not labelled, three months to 2024-06-30−$12.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure(13.5)Operating income, Q3 FY2024, three months to 2024-09-30−$13.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure(14.0)Operating income, Q4 FY2024, three months to 2024-12-31−$14.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(13.1)Operating income, Q1 FY2025, three months to 2025-03-31−$13.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure(13.0)Operating income, Q2 FY2025, three months to 2025-06-30−$13.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure(13.7)Operating income, Q3 FY2025, three months to 2025-09-30−$13.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure(12.8)Operating income, Q4 FY2025, three months to 2025-12-31−$12.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(13.1)Operating income, Q1 FY2026, three months to 2026-03-31−$13.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure(13.4)Operating income, Q2 FY2026, three months to 2026-06-30−$13.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Income tax$m0.0Income tax, period not labelled, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure0.0Income tax, period not labelled, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-27, accession 0001736730-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, period not labelled, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure0.0Income tax, period not labelled, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Net income$m(11.7)Net income, period not labelled, three months to 2023-09-30−$11.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure(13.0)Net income, period not labelled, three months to 2023-12-31−$13.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-27, accession 0001736730-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure(12.5)Net income, period not labelled, three months to 2024-03-31−$12.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure(12.6)Net income, period not labelled, three months to 2024-06-30−$12.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure(13.5)Net income, Q3 FY2024, three months to 2024-09-30−$13.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure(13.3)Net income, Q4 FY2024, three months to 2024-12-31−$13.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(12.4)Net income, Q1 FY2025, three months to 2025-03-31−$12.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure(12.6)Net income, Q2 FY2025, three months to 2025-06-30−$12.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure(15.1)Net income, Q3 FY2025, three months to 2025-09-30−$15.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure(40.3)Net income, Q4 FY2025, three months to 2025-12-31−$40.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(18.3)Net income, Q1 FY2026, three months to 2026-03-31−$18.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure(33.5)Net income, Q2 FY2026, three months to 2026-06-30−$33.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Diluted EPS$ per share(29.21)Diluted EPS, period not labelled, three months to 2023-09-30−$29.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figurenot reported(26.57)Diluted EPS, period not labelled, three months to 2024-03-31−$26.57 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure(26.00)Diluted EPS, period not labelled, three months to 2024-06-30−$26.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure(24.19)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$24.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figurenot reported(0.62)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure(0.62)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure(0.55)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figurenot reported(0.32)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure(0.58)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Basic EPS$ per share(29.21)Basic EPS, period not labelled, three months to 2023-09-30−$29.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figurenot reported(26.57)Basic EPS, period not labelled, three months to 2024-03-31−$26.57 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure(26.00)Basic EPS, period not labelled, three months to 2024-06-30−$26.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure(24.19)Basic EPS, Q3 FY2024, three months to 2024-09-30−$24.19 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figurenot reported(0.62)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure(0.62)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure(0.55)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figurenot reported(0.32)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.32 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure(0.58)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.58 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure

Balance sheet

Cash and equivalents$86.4m, Q2 FY2026
Shareholders' equity−$693.0k, Q2 FY2026
Camp4 Therapeutics Corp, balance sheet, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2023-12-31period not labelled2024-03-31period not labelled2024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m50.5Cash and equivalents, period not labelled, at 2023-09-30$50.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure38.4Cash and equivalents, period not labelled, at 2023-12-31$38.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-03-27, accession 0001736730-25-000022.Report this figurenot reportednot reported2.5Cash and equivalents, Q3 FY2024, at 2024-09-30$2.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure64.0Cash and equivalents, FY2024, at 2024-12-31$64.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-05, accession 0001736730-26-000016.Report this figure49.3Cash and equivalents, Q1 FY2025, at 2025-03-31$49.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure39.1Cash and equivalents, Q2 FY2025, at 2025-06-30$39.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure75.3Cash and equivalents, Q3 FY2025, at 2025-09-30$75.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure110Cash and equivalents, FY2025, at 2025-12-31$109.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure99.2Cash and equivalents, Q1 FY2026, at 2026-03-31$99.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure86.4Cash and equivalents, Q2 FY2026, at 2026-06-30$86.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Current assets$mnot reported40.0Current assets, period not labelled, at 2023-12-31$40.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-27, accession 0001736730-25-000022.Report this figurenot reportednot reported5.5Current assets, Q3 FY2024, at 2024-09-30$5.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure66.4Current assets, FY2024, at 2024-12-31$66.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-05, accession 0001736730-26-000016.Report this figure51.7Current assets, Q1 FY2025, at 2025-03-31$51.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure41.1Current assets, Q2 FY2025, at 2025-06-30$41.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure77.7Current assets, Q3 FY2025, at 2025-09-30$77.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure114Current assets, FY2025, at 2025-12-31$114.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure102Current assets, Q1 FY2026, at 2026-03-31$102.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure90.0Current assets, Q2 FY2026, at 2026-06-30$90.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Total assets$mnot reported54.9Total assets, period not labelled, at 2023-12-31$54.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-27, accession 0001736730-25-000022.Report this figurenot reportednot reported21.4Total assets, Q3 FY2024, at 2024-09-30$21.4m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure78.3Total assets, FY2024, at 2024-12-31$78.3m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-05, accession 0001736730-26-000016.Report this figure62.8Total assets, Q1 FY2025, at 2025-03-31$62.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure51.3Total assets, Q2 FY2025, at 2025-06-30$51.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure86.4Total assets, Q3 FY2025, at 2025-09-30$86.4m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure118Total assets, FY2025, at 2025-12-31$117.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure105Total assets, Q1 FY2026, at 2026-03-31$105.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure93.4Total assets, Q2 FY2026, at 2026-06-30$93.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Current liabilities$mnot reported7.8Current liabilities, period not labelled, at 2023-12-31$7.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-27, accession 0001736730-25-000022.Report this figurenot reportednot reported11.8Current liabilities, Q3 FY2024, at 2024-09-30$11.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure9.6Current liabilities, FY2024, at 2024-12-31$9.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-05, accession 0001736730-26-000016.Report this figure6.4Current liabilities, Q1 FY2025, at 2025-03-31$6.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure7.3Current liabilities, Q2 FY2025, at 2025-06-30$7.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure7.9Current liabilities, Q3 FY2025, at 2025-09-30$7.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure15.5Current liabilities, FY2025, at 2025-12-31$15.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure16.6Current liabilities, Q1 FY2026, at 2026-03-31$16.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure19.1Current liabilities, Q2 FY2026, at 2026-06-30$19.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Total liabilities$mnot reported16.5Total liabilities, period not labelled, at 2023-12-31$16.5m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-27, accession 0001736730-25-000022.Report this figurenot reportednot reported18.2Total liabilities, Q3 FY2024, at 2024-09-30$18.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure15.2Total liabilities, FY2024, at 2024-12-31$15.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-05, accession 0001736730-26-000016.Report this figure11.2Total liabilities, Q1 FY2025, at 2025-03-31$11.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure11.3Total liabilities, Q2 FY2025, at 2025-06-30$11.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure27.7Total liabilities, Q3 FY2025, at 2025-09-30$27.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure70.1Total liabilities, FY2025, at 2025-12-31$70.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure74.6Total liabilities, Q1 FY2026, at 2026-03-31$74.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure94.1Total liabilities, Q2 FY2026, at 2026-06-30$94.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure
Shareholders' equity$m(112)Shareholders' equity, period not labelled, at 2023-09-30−$111.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure(124)Shareholders' equity, period not labelled, at 2023-12-31−$123.7m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-05, accession 0001736730-26-000016.Report this figure(135)Shareholders' equity, period not labelled, at 2024-03-31−$135.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure(147)Shareholders' equity, period not labelled, at 2024-06-30−$147.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure(159)Shareholders' equity, Q3 FY2024, at 2024-09-30−$159.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure63.1Shareholders' equity, FY2024, at 2024-12-31$63.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure51.6Shareholders' equity, Q1 FY2025, at 2025-03-31$51.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure40.0Shareholders' equity, Q2 FY2025, at 2025-06-30$40.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure58.7Shareholders' equity, Q3 FY2025, at 2025-09-30$58.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure47.7Shareholders' equity, FY2025, at 2025-12-31$47.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure30.9Shareholders' equity, Q1 FY2026, at 2026-03-31$30.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure(0.7)Shareholders' equity, Q2 FY2026, at 2026-06-30−$693.0k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure

Cash flow

Operating cash flow−$12.7m, Q2 FY2026
Capital expenditure$129.0k, Q2 FY2026
Camp4 Therapeutics Corp, cash flow, quarterly
Line itemUnitperiod not labelled2023-12-31period not labelled2024-03-31period not labelled2024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(11.8)Operating cash flow, period not labelled, three months to 2023-12-31−$11.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-27, accession 0001736730-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure(11.1)Operating cash flow, period not labelled, three months to 2024-03-31−$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure(13.4)Operating cash flow, period not labelled, three months to 2024-06-30−$13.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-14, accession 0001736730-25-000070. Derived: 6-month figure less the 3-month figure.Report this figure(9.7)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$9.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001736730-25-000094. Derived: 9-month figure less the 6-month figure.Report this figure(11.3)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$11.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(14.3)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$14.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure(10.3)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$10.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001628280-26-056760. Derived: 6-month figure less the 3-month figure.Report this figure(11.2)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$11.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001736730-25-000094. Derived: 9-month figure less the 6-month figure.Report this figure6.3Operating cash flow, Q4 FY2025, three months to 2025-12-31$6.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure(11.0)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$11.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure(12.7)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$12.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001628280-26-056760. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.2Capital expenditure, period not labelled, three months to 2023-12-31$243.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-27, accession 0001736730-25-000022. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, period not labelled, three months to 2024-03-31$15.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure0.2Capital expenditure, period not labelled, three months to 2024-06-30$163.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-14, accession 0001736730-25-000070. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001736730-25-000094. Derived: 9-month figure less the 6-month figure.Report this figure0.3Capital expenditure, Q4 FY2024, three months to 2024-12-31$263.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.3Capital expenditure, Q1 FY2025, three months to 2025-03-31$279.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001628280-26-056760. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001736730-25-000094. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001736730-26-000016. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure0.1Capital expenditure, Q2 FY2026, three months to 2026-06-30$129.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001628280-26-056760. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)57.93m, Q2 FY2026
Camp4 Therapeutics Corp, shares, quarterly
Line itemUnitperiod not labelled2023-09-30period not labelled2024-03-31period not labelled2024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.4Diluted shares (weighted), period not labelled, three months to 2023-09-30400,426 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-21, accession 0001410578-24-002045.Report this figure0.5Diluted shares (weighted), period not labelled, three months to 2024-03-31468,695 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001736730-25-000039.Report this figure0.5Diluted shares (weighted), period not labelled, three months to 2024-06-30483,640 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-14, accession 0001736730-25-000070.Report this figure0.6Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30557,437 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure20.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3120,152,872 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure20.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3020,159,666 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure27.3Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3027,274,721 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001736730-25-000094.Report this figure57.9Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3157,923,674 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001628280-26-032146.Report this figure57.9Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3057,929,662 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure

Shares outstanding: 62.75mShares outstanding, period not labelled, at 2026-08-1262,753,200 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-13, accession 0001628280-26-056760.Report this figure at Aug 12, 2026, from the cover of the 10-Q filed Aug 13, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.